# Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation

> **NCT06178926** · NA · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Liver Cancer
- Ciprofol

## Interventions

- **DRUG:** Propofol
- **DRUG:** Ciprofol

## Key facts

- **NCT ID:** NCT06178926
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06178926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06178926, "Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06178926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*